Why Aphria Inc. Ought to Ditch TSX

Aphria Inc. (TSX:APH), one of the best run Canadian cannabis companies, ought to call the TSX’s bluff and move to another exchange. 

| More on:

Two of my Fool.ca colleagues recently warned that Aphria Inc. (TSX:APH) is playing with fire by holding interests in U.S. cannabis businesses because that potentially puts it offside with both the U.S. Attorney General’s office and the mighty Toronto Stock Exchange.

I have three words for Aphria CEO Vic Neufeld: Call their bluff!

What’s the real risk here?

I believe in assessing stocks based on what I know rather than speculation by others. In recent months there has been a great deal of chatter about the TSX rattling its sword to keep all of its listed companies in line.

The TSX is concerned about Aphria because of its dealings in the U.S. — a nation so hopelessly divided at the moment that the exchange is concerned that Neufeld will be thrown in jail south of the border — taking the good name of the exchange down with him.

I’m being facetious, of course, but in my opinion, the exchange ought to stay out of Aphria’s business for two reasons.

“The U.S. government continues to take a tough stance on marijuana, and Attorney General Jeff Sessions only further complicated things when he stated that federal laws on pot could still be enforced in states where the drug has been legalized,” wrote David Jagielski on January 12. “This legal ambiguity creates a lot of uncertainty for investors, and it’s hard to understand why Aphria would risk running into problems down the road.”

No legitimate business wants to run afoul of the law, especially not a growing cannabis company with a market cap of $3.5 billion.

However, Americans take state rights very seriously.

In a recent poll by HuffPost/YouGov, only 30% of Americans said they would back a move by federal prosecutors to stop the sale and use of marijuana in states where pot is legal. Aphria’s U.S. investments are in Florida and Arizona, where medical marijuana is legal.

Jeff Sessions can do and say whatever he wants, but should the rights of Americans be trampled upon in states where medical and recreational marijuana is legal, you can be sure that there will be years of litigation and court proceedings to protect those rights.

What about the TSX?

As I said earlier, the TSX ought to mind its own business. There’s a difference between believing a listed company is doing something illegal and a lawyer’s opinion that they could be.

However, if the TSX continues to play a game of chicken, I believe that Neufeld ought to take his company’s business elsewhere. There are places to list right here in Canada that would gladly have it — the Canadian Securities Exchange being one; Aequitas Neo Exchange being another. 

The CSE has 53 cannabis issuers listed on its exchange; 17 of them doing business in the U.S. Those 17 companies account for 25% of the CSE’s entire market cap. I’m sure CSE CEO Richard Carlton would have no problem welcoming Aphria into the fold. 

Fool.ca contributor Joey Frenette likens Aphria’s situation to Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) in that Aphria could be forced to sell its U.S. assets quickly at prices that are less than optimal in order to comply with TSX rules and the U.S. Attorney General.

I fail to see how one has anything to do with the other.

Valeant had to unload assets or its bankers would have come calling, hat in hand.

Aphria, on the other hand, has done everything to comply with the laws in the jurisdictions in which they operate. There’s almost zero chance that the company would not be given an opportunity to sell those assets in a way that meets the needs of shareholders.

Chances are, however, it won’t come to that.

Bottom line

The TSX is proving once more why exchanges like the CSE are growing in stature. The TSX’s sabre rattling is both perplexing and counterproductive to building an entrepreneurial, pro-business environment for companies to raise capital in this country.

Take a pass on Aphria stock if you must, but don’t let your decision be guided by conjecture and speculation because at the end of the day, Aphria does have options — good ones, in fact.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Will Ashworth has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

ETF stands for Exchange Traded Fund
Investing

Passive Income Investors: This TSX Fund Has a 7.6% Yield With Monthly Payouts

Here's all you need to know about the Canoe EIT Income Fund (TSX:EIT.UN)

Read more »

stock research, analyze data
Tech Stocks

Apple vs. Shopify: Which Stock Is the Better Buy for the Next 3 Years?

Apple (NASDAQ:AAPL) and Shopify (TSX:SHOP) are great tech titans, but they're ending the year with huge momentum.

Read more »

Investor reading the newspaper
Dividend Stocks

Emerging Investment Trends to Watch for in 2025

Canadians must watch out for and be guided by emerging investment trends to ensure financial success in 2025.

Read more »

RRSP Canadian Registered Retirement Savings Plan concept
Dividend Stocks

Watch Out! This is the Maximum Canadians Can Contribute to Their RRSP

We often discuss the maximum TFSA amount, but did you know there's a max for the RRSP as well? Here's…

Read more »

nvidia headquarters with grey nvidia sign in front with nvidia logo
Tech Stocks

If You’d Invested $100/Month in Nvidia Starting a Decade Ago, Here’s How Much You’d Have Now

Nvidia has helped long-term investors create generational wealth. But is the tech stock still a good buy right now?

Read more »

chart reflected in eyeglass lenses
Tech Stocks

Is Shopify Stock a Buy, Sell, or Hold for 2025?

Shopify (TSX:SHOP) still looks like a tempting growth stock going into a new year with strength.

Read more »

Electricity transmission towers with orange glowing wires against night sky
Dividend Stocks

Outlook for Fortis Stock in 2025

Fortis stock is up 10% in 2024. Are more gains on the way?

Read more »

Canadian energy stocks are rising with oil prices
Dividend Stocks

3 Low-Volatility Stocks for Cautious Investors

As uncertainty grips the market, here are three low-volatility stocks you can buy and hold with confidence.

Read more »